drugset / Trial / NCT04838808
Rivaroxaban in Type 2 Myocardial Infarctions
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major cardiovascular events.
Timeline
- Start
- 2021-04-05
- Primary completion
- 2022-05-12
- Completion
- 2023-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rivaroxaban | Other / unclassified | 2.5 mg | Oral |